Cipla has elevated Samina Vaziralli, part of the firm's founding family, to its board, amid a series of top level exits that have rocked the company over the recent past.
Cipla heiress joins board as family fortifies "commitment"
Cipla has elevated Samina Vaziralli, part of the firm's founding family, to its board, amid a series of top level exits that have rocked the company over the recent past.
More from Neurological
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.